TY - JOUR
T1 - Pancreatic cancer survival by stage and age in seven high-income countries (ICBP SURVMARK-2)
T2 - a population-based study
AU - Cabasag, Citadel J.
AU - Arnold, Melina
AU - Rutherford, Mark
AU - Bardot, Aude
AU - Ferlay, Jacques
AU - Morgan, Eileen
AU - Little, Alana
AU - De, Prithwish
AU - Dixon, Elijah
AU - Woods, Ryan R.
AU - Saint-Jacques, Nathalie
AU - Evans, Sue
AU - Engholm, Gerda
AU - Elwood, Mark
AU - Merrett, Neil
AU - Ransom, David
AU - O’Connell, Dianne L.
AU - Bray, Freddie
AU - Soerjomataram, Isabelle
N1 - Funding Information:
The authors would like to thank the ICBP management team of Cancer Research UK for managing the programme, the ICBP SURVMARK-2 Local Leads for advice to understand the data, for their contributions to the study protocol, and interpretation of the results, as well as, the ICBP Clinical Committees for their advice. We are grateful to the ICBP SurvMark-2 Academic Reference Group for providing independent peer review and advice for the study protocol and analysis plan development. Finally, we thank the ICBP Program Board for their oversight and direction. A complete list of all investigators can be found in Supplementary Information Table 8. ICBP is funded by the Canadian Partnership Against Cancer; Cancer Council Victoria; Cancer Institute New South Wales; Cancer Research UK; Danish Cancer Society; National Cancer Registry Ireland; The Cancer Society of New Zealand; NHS England; Norwegian Cancer Society; Public Health Agency Northern Ireland on behalf of the Northern Ireland Cancer Registry; DG Health and Social Care, Scottish Government; Western Australia Department of Health; Public Health Wales NHS Trust.
Funding Information:
The authors would like to thank the ICBP management team of Cancer Research UK for managing the programme, the ICBP SURVMARK-2 Local Leads for advice to understand the data, for their contributions to the study protocol, and interpretation of the results, as well as, the ICBP Clinical Committees for their advice. We are grateful to the ICBP SurvMark-2 Academic Reference Group for providing independent peer review and advice for the study protocol and analysis plan development. Finally, we thank the ICBP Program Board for their oversight and direction. A complete list of all investigators can be found in Supplementary Information Table . ICBP is funded by the Canadian Partnership Against Cancer; Cancer Council Victoria; Cancer Institute New South Wales; Cancer Research UK; Danish Cancer Society; National Cancer Registry Ireland; The Cancer Society of New Zealand; NHS England; Norwegian Cancer Society; Public Health Agency Northern Ireland on behalf of the Northern Ireland Cancer Registry; DG Health and Social Care, Scottish Government; Western Australia Department of Health; Public Health Wales NHS Trust.
Publisher Copyright:
© 2022, The Author(s), under exclusive licence to Springer Nature Limited.
PY - 2022/6/1
Y1 - 2022/6/1
N2 - Background: The global burden of pancreatic cancer has steadily increased, while the prognosis after pancreatic cancer diagnosis remains poor. This study aims to compare the stage- and age-specific pancreatic cancer net survival (NS) for seven high-income countries: Australia, Canada, Denmark, Ireland, New Zealand, Norway, and United Kingdom. Methods: The study included over 35,000 pancreatic cancer cases diagnosed during 2012–2014, followed through 31 December 2015. The stage- and age-specific NS were calculated using the Pohar-Perme estimator. Results: Pancreatic cancer survival estimates were low across all 7 countries, with 1-year NS ranging from 21.1% in New Zealand to 30.9% in Australia, and 3-year NS from 6.6% in the UK to 10.9% in Australia. Most pancreatic cancers were diagnosed with distant stage, ranging from 53.9% in Ireland to 83.3% in New Zealand. While survival differences were evident between countries across all stage categories at one year after diagnosis, this survival advantage diminished, particularly in cases with distant stage. Conclusion: This study demonstrated the importance of stage and age at diagnosis in pancreatic cancer survival. Although progress has been made in improving pancreatic cancer prognosis, the disease is highly fatal and will remain so without major breakthroughs in the early diagnosis and management.
AB - Background: The global burden of pancreatic cancer has steadily increased, while the prognosis after pancreatic cancer diagnosis remains poor. This study aims to compare the stage- and age-specific pancreatic cancer net survival (NS) for seven high-income countries: Australia, Canada, Denmark, Ireland, New Zealand, Norway, and United Kingdom. Methods: The study included over 35,000 pancreatic cancer cases diagnosed during 2012–2014, followed through 31 December 2015. The stage- and age-specific NS were calculated using the Pohar-Perme estimator. Results: Pancreatic cancer survival estimates were low across all 7 countries, with 1-year NS ranging from 21.1% in New Zealand to 30.9% in Australia, and 3-year NS from 6.6% in the UK to 10.9% in Australia. Most pancreatic cancers were diagnosed with distant stage, ranging from 53.9% in Ireland to 83.3% in New Zealand. While survival differences were evident between countries across all stage categories at one year after diagnosis, this survival advantage diminished, particularly in cases with distant stage. Conclusion: This study demonstrated the importance of stage and age at diagnosis in pancreatic cancer survival. Although progress has been made in improving pancreatic cancer prognosis, the disease is highly fatal and will remain so without major breakthroughs in the early diagnosis and management.
UR - http://www.scopus.com/inward/record.url?scp=85125522738&partnerID=8YFLogxK
U2 - 10.1038/s41416-022-01752-3
DO - 10.1038/s41416-022-01752-3
M3 - Article
C2 - 35236937
AN - SCOPUS:85125522738
VL - 126
SP - 1774
EP - 1782
JO - British Journal of Cancer
JF - British Journal of Cancer
SN - 0007-0920
IS - 12
ER -
